<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCDSA</journal-id><journal-title-group><journal-title>Journal of Cosmetics, Dermatological Sciences and Applications</journal-title></journal-title-group><issn pub-type="epub">2161-4105</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jcdsa.2015.52019</article-id><article-id pub-id-type="publisher-id">JCDSA-57497</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Evolution of Post-Surgical Scars Treated with Pure Rosehip Seed Oil
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>edro</surname><given-names>Valerón-Almazán</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Anselmo</surname><given-names>J. Gómez-Duaso</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Néstor</surname><given-names>Santana-Molina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Miguel</surname><given-names>A. García-Bello</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gregorio</surname><given-names>Carretero</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Dermatology Service, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas, Spain</addr-line></aff><aff id="aff2"><addr-line>Research Unit, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas, Spain</addr-line></aff><pub-date pub-type="epub"><day>20</day><month>03</month><year>2015</year></pub-date><volume>05</volume><issue>02</issue><fpage>161</fpage><lpage>167</lpage><history><date date-type="received"><day>28</day>	<month>May</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>26</month>	<year>June</year>	</date><date date-type="accepted"><day>29</day>	<month>June</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  The rosehip seed oil (RHO), obtained from different plant species of the genus Rosa, is one of the compounds used empirically for cosmetic improvement of skin scarring. Despite its widespread use in clinical practice, there are few studies evaluating the activity of this compound on the clinical course of cutaneous scars. The aim of this study was to determine the effect of Repavar&amp;reg
   rosehip oil on improvement of post-surgical skin scars. One comparative, single-center, prospective clinical trial was carried out in 108 patients undergoing cutaneous surgery procedures in the Dermatology Service of University Hospital of Gran Canaria Dr. Negr&#237;n (Spain). Subjective parameters (ery
  thema, discoloration, atrophy and hypertrophy) were evaluated at 6 and 12 weeks on 76 adults 
  who treated scars with pure RHO twice a day (test group), 32 patients with not treatment (control group), and completed the study. Lesser degree of erythema was observed at 6 and 12 weeks in treated-patients compared with the control group and decreased discoloration and atrophy at 12 weeks, with statistically significant differences in all cases (p &lt; 0.05). This study demonstrates that the RHO Repavar&amp;reg
   is useful for cosmetic improvement on erythema, discoloration and atrophyof post-surgical skin scars, getting a better overall evolution and appearance thereof.
 
</p></abstract><kwd-group><kwd>Healing</kwd><kwd> Skin Scar</kwd><kwd> Rosa Mosqueta</kwd><kwd> Rosehip Seed Oil</kwd><kwd> Skin Surgery</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Healing is a natural and dynamic process in which body has to regenerate tissues after injury. This process develops along three phases, comprising inflammation, granulation tissue formation and maturation/remodeling [<xref ref-type="bibr" rid="scirp.57497-ref1">1</xref>] -[<xref ref-type="bibr" rid="scirp.57497-ref3">3</xref>] . In the inflammatory phase, platelet degranulation, cell-recruitment migration, and extracellular matrix formation are initiated, all mediated by multiple cytokines and growth factors [<xref ref-type="bibr" rid="scirp.57497-ref4">4</xref>] . The proliferative phase starts several days after the initial injury, and it is characterized by angiogenesis, collagen deposition, formation of granulation tissue and epithelialization and contraction of the scar [<xref ref-type="bibr" rid="scirp.57497-ref5">5</xref>] . In the remodeling phase, tissue enzymes remove excess of extracellular matrix and collagen, and remained fibrils are realigned along the tension lines. This remodeling process occurs during 6 - 12 months but may persist for years after initial injury [<xref ref-type="bibr" rid="scirp.57497-ref3">3</xref>] .</p><p>Clinically, cutaneous scars are defined as macroscopic alterations of the architectural structure of the skin, as a final result of the healing process. The affected area may be displayed as an elevated or depressed area, which has also variations in consistency, color, vascularization and/or innervation. Although many therapies have been tried to improve the clinical appearance of skin scars, no treatment has clearly shown its efficacy and still considers prevention as the most important attitude to avoid the appearance of hypertrophic scars or keloids [<xref ref-type="bibr" rid="scirp.57497-ref6">6</xref>] .</p><p>“Rosa mosqueta” or “Rosehip”, is a generic name which covers about 70 different species of plants of the genus Rosa, as Rosa rubiginosa, Rosa moschata and Rosa canina [<xref ref-type="bibr" rid="scirp.57497-ref7">7</xref>] . The rosehip seed oil (RHO) is extracted from the seed of the fruit of the wild plant. Some studies have examined before the chemical composition of this compound, where the high content of polyunsaturated fatty acid highlights: linoleic acid (54%), linolenic acid (17%) and oleic acid (16%) between others [<xref ref-type="bibr" rid="scirp.57497-ref8">8</xref>] . Lesser amounts of other saturated fatty acids and small amounts of other dermatological active interest like transretinoic acid or natural tretinoin (between 0.01% and 0.1%) have also been identified [<xref ref-type="bibr" rid="scirp.57497-ref9">9</xref>] .</p><p>In the medical field, the RHO has been used for decades to treat wounds and/or scars. The beneficial effect of this oil has been attributed to its high content of essential fatty and unsaturated acids abovementioned, which play a key role in the permeability of cell membranes and injuries repair mechanisms [<xref ref-type="bibr" rid="scirp.57497-ref10">10</xref>] . Despite its theoretical utility in these processes, there are few studies that evaluate the activity of this compound on the clinical course of healing [<xref ref-type="bibr" rid="scirp.57497-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.57497-ref12">12</xref>] .</p><p>The aim of this study was to analyze the clinical course of post-surgical cutaneous scars treated with pure RHO in terms of erythema, discoloration, atrophy and hypertrophy.</p></sec><sec id="s2"><title>2. Methods</title><sec id="s2_1"><title>2.1. Patients</title><p>108 patients were underwent open surgical procedures for skin tumor removal of pigmented lesions between April and June (over three months), in the Dermatology Service, University Hospital of Gran Canaria Dr. Negr&#237;n, were enrolled in a comparative, single-center and prospective study.</p><p>Inclusion criteria in the study were elderly patients with sufficient level of understanding, with not-known- RHO-allergies, without any history of keloids or other healing defects.</p><p>The Clinical Research Ethics Committee of the Hospital approved the study, and all patients gave informed consent form to participate in it.</p></sec><sec id="s2_2"><title>2.2. Treatment</title><p>Patients in the test group had to apply the RHO (Repavar<sup>&#174;</sup>) twice a day on the scar, from the removal of sutures, for six weeks. Patients considered as controls did not perform any treatment.</p><p>Patients were assigned to each group randomly and the same experienced dermatologist performed the evaluation in all groups of patients, so that all observations follow the same validated criteria.</p></sec><sec id="s2_3"><title>2.3. Analysis Parameters</title><p>The variables were analyzed at 6 and 12 weeks after removal of sutures, and data were recorded taking into account this classification (<xref ref-type="table" rid="table1">Table 1</xref>):</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Evaluation criteria of parameters erythema, discoloration, atrophy and hypertrophy</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Erythema</th><th align="center" valign="middle"  colspan="2"  >Dyschromia</th><th align="center" valign="middle"  colspan="2"  >Atrophy</th><th align="center" valign="middle"  colspan="2"  >Hypertrophy</th></tr></thead><tr><td align="center" valign="middle" >0</td><td align="center" valign="middle" >No erythema</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >No color change</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >No atrophy</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >No hypertrophy</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Mild (pink)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Slight hyper/hypochromia</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Slight depression</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Slight hypertrophy</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Intense (red)</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Major hyper/hypochromia</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Major depression</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Major hypertrophy (keloid)</td></tr></tbody></table></table-wrap><p>For the descriptive analysis, categorical variables were expressed as absolute frequencies and percentages.</p></sec><sec id="s2_4"><title>2.4. Statistical Analysis</title><p>For statistical analysis, the Chi-square test was used, considering a level of statistical significance α &lt; 0.05.</p></sec></sec><sec id="s3"><title>3. Results and Discussion</title><p>A total of 160 patients were included in the trial, of whom 120 patients were treated with RHO and 40 underwent no treatment (control).</p><p>103 patients from the 120 treated patients group attended the review of 6 weeks and 76 attended the review of the 12 weeks. 32 patients from the 40 patients control group went to the reviews at 6 and 12 weeks. 108 patients completed the study.</p><p>No adverse effects were observed in any patient, neither in the treated group and the control group.</p><p><xref ref-type="table" rid="table2">Table 2</xref> and Figures 1-4 summarize the results.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Evolution of patients at 6 and 12 weeks</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" >Treated-group</th><th align="center" valign="middle" >Control group</th><th align="center" valign="middle" >Total</th></tr></thead><tr><td align="center" valign="middle"  colspan="5"  >Erythema</td></tr><tr><td align="center" valign="middle" >6 weeks</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >61 (52.9%)</td><td align="center" valign="middle" >14 (43.8%)</td><td align="center" valign="middle" >75</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >38 (36.9%)</td><td align="center" valign="middle" >11 (34.4%)</td><td align="center" valign="middle" >49</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Intense</td><td align="center" valign="middle" >4 (3.9%)</td><td align="center" valign="middle" >7 (21.9%)</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >12 weeks</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >56 (73.7%)</td><td align="center" valign="middle" >16 (50.0%)</td><td align="center" valign="middle" >72</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >15 (19.7%)</td><td align="center" valign="middle" >9 (28.1%)</td><td align="center" valign="middle" >24</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Intense</td><td align="center" valign="middle" >5 (6.6%)</td><td align="center" valign="middle" >7 (21.9%)</td><td align="center" valign="middle" >12</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Dischromia</td></tr><tr><td align="center" valign="middle" >6 weeks</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >29 (28.2%)</td><td align="center" valign="middle" >10 (31.3%)</td><td align="center" valign="middle" >39</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >67 (65.2%)</td><td align="center" valign="middle" >18 (56.3%)</td><td align="center" valign="middle" >85</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Intense</td><td align="center" valign="middle" >7 (6.8%)</td><td align="center" valign="middle" >4 (12.5%)</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >12 weeks</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >48 (63.2%)</td><td align="center" valign="middle" >7 (21.9%)</td><td align="center" valign="middle" >55</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >24 (31.6%)</td><td align="center" valign="middle" >22 (68.8%)</td><td align="center" valign="middle" >46</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Intense</td><td align="center" valign="middle" >4 (5.3%)</td><td align="center" valign="middle" >3 (9.4%)</td><td align="center" valign="middle" >7</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Atrophy</td></tr><tr><td align="center" valign="middle" >6 weeks</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >83 (80.6%)</td><td align="center" valign="middle" >23 (71.9%)</td><td align="center" valign="middle" >106</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >18 (17.5%)</td><td align="center" valign="middle" >7 (21.9%)</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Notorious</td><td align="center" valign="middle" >2 (1.9%)</td><td align="center" valign="middle" >2 (6.3%)</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >12 weeks</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >65 (85.5%)</td><td align="center" valign="middle" >20 (62.5%)</td><td align="center" valign="middle" >85</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >9 (11.8%)</td><td align="center" valign="middle" >9 (28.1%)</td><td align="center" valign="middle" >18</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Notorious</td><td align="center" valign="middle" >2 (2.6%)</td><td align="center" valign="middle" >3 (9.4%)</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Hypertrophy</td></tr><tr><td align="center" valign="middle" >6 weeks</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >83 (80.6%)</td><td align="center" valign="middle" >26 (81.2%)</td><td align="center" valign="middle" >109</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >14 (13.6%)</td><td align="center" valign="middle" >4 (12.5%)</td><td align="center" valign="middle" >18</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Intense</td><td align="center" valign="middle" >6 (5.8%)</td><td align="center" valign="middle" >2 (6.2%)</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >12 weeks</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >67 (89.3%)</td><td align="center" valign="middle" >25 (78.1%)</td><td align="center" valign="middle" >72</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >7 (9.4%)</td><td align="center" valign="middle" >6 (18.8%)</td><td align="center" valign="middle" >24</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Intense</td><td align="center" valign="middle" >1 (1.3%)</td><td align="center" valign="middle" >1 (3.1%)</td><td align="center" valign="middle" >12</td></tr></tbody></table></table-wrap><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Subjective evaluation of erythema at 6 and 12 weeks. Blue bar, intense; red bar, mild; green bar, no erythema</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/13-1050307x5.png"/></fig><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Subjective evaluation of discoloration at 6 and 12 weeks. Blue bar, intense; red bar, mild; green bar, no discoloration</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/13-1050307x6.png"/></fig><fig id="fig3"  position="float"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> Subjective evaluation of atrophy at 6 and 12 weeks. Blue bar, notorious; red bar, mild; green bar, no atrophy</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/13-1050307x7.png"/></fig><p>In the subjective assessment of erythema carried out by the specialist (<xref ref-type="fig" rid="fig1">Figure 1</xref>), significant differences between the patients and the control group at both 6 and 12 weeks (73% of treated patients did not presented erythema at 12 weeks vs. 50% of control patients) were founded.</p><p>Concerning the colorimetric changes taken together, a higher proportion of patients treated with RHO did not shown subjective discoloration at 6 and 12 weeks, although these differences were only significant at 12 weeks (63% of treated patients without discoloration vs. 21% control) (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><fig id="fig4"  position="float"><label><xref ref-type="fig" rid="fig4">Figure 4</xref></label><caption><title> Subjective evaluation of hypertrophy at 6 and 12 weeks. Blue bar, notorious; red bar, mild; green bar, no hypertrophy</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/13-1050307x8.png"/></fig><p>The atrophy measurement (<xref ref-type="fig" rid="fig3">Figure 3</xref>) showed differences in patients treated with RHO at 6 and 12 weeks, with significant differences at the second examination (85% vs. 62% of patients without atrophy found at 12 weeks).</p><p>Finally, hypertrophy analysis showed better evolution of scars on treated-group compared to control group at 6 and 12 weeks, but no statistically significant differences (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p><xref ref-type="fig" rid="fig5">Figure 5</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref> show two examples of cutaneous scars treated with RHO, at the beginning of treatment (<xref ref-type="fig" rid="fig5">Figure 5</xref>(A) and <xref ref-type="fig" rid="fig6">Figure 6</xref>(A)) and after 12 weeks (<xref ref-type="fig" rid="fig5">Figure 5</xref>(B) and <xref ref-type="fig" rid="fig6">Figure 6</xref>(B)).</p><p>In daily dermatological practice, it is common that patients in whom a common surgical procedure is practiced not receive any topical treatment for cosmetic improvement after removal of sutures, beyond sunscreen always recommended. In this study, RHO showed a beneficial effect on clinical appearance of scars, in general, compared with those who were remained to their natural evolution. Our observations are concurrent with previous studies that evaluated the properties of RHO in healing injuries [<xref ref-type="bibr" rid="scirp.57497-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.57497-ref12">12</xref>] .</p><p>Within the parameters analyzed, the most obvious improvement occurred in terms of erythema, with statistically significant differences in medical analysis at both 6 and 12 weeks in the RHO-treated-patients group (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In the evolution of post-operative dyschromia, only significant differences at 12 weeks were found. It is possible that the scars color improvement may be associated with reduced inflammation [<xref ref-type="bibr" rid="scirp.57497-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.57497-ref14">14</xref>] and inhibition of chemotaxis [<xref ref-type="bibr" rid="scirp.57497-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.57497-ref16">16</xref>] that has been shown in in vitro and in vivo clinical trials using Rosehip seed oil.</p><p>A previous study used histological criteria to evaluate therapeutic properties of RHO [<xref ref-type="bibr" rid="scirp.57497-ref13">13</xref>] , but we discard this possibility because the procedure was so invasive.</p><p>Several studies have found high levels of unsaturated fatty acids in RHO, mainly linoleic acid, linolenic acid and oleic acid [<xref ref-type="bibr" rid="scirp.57497-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.57497-ref9">9</xref>] . Essential fatty acids are basic components of the phospholipids in cell membranes, which are involved in numerous phosphorylation and cellular organization processes [<xref ref-type="bibr" rid="scirp.57497-ref10">10</xref>] . Some compounds like carotenoids and polyphenols have also been isolated from the RHO [<xref ref-type="bibr" rid="scirp.57497-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.57497-ref18">18</xref>] , which are responsible for the antioxidant activity attributed to this compound. It is possible that the presence of these substances in the RHO contribute to a better evolution of the healing process, especially if it is applied early, as happened in our patients.</p><p>In the assessment of atrophy, a higher percentage of patients with outatrophy at 12 weeks, was found with significant differences, in the RHO-treated-group(85% vs. 62%). These differences may be related to the presence of derivatives of vitamin A (retinoic acid or naturally tretinoin) that have been previously identified in RHO [<xref ref-type="bibr" rid="scirp.57497-ref9">9</xref>] . Tretinoin topical treatment is widely used in dermatology, mainly in the context of acne vulgaris [<xref ref-type="bibr" rid="scirp.57497-ref19">19</xref>] and photo-induced skin damage [<xref ref-type="bibr" rid="scirp.57497-ref20">20</xref>] , although previous references also exist about the benefit of its use in healing injury [<xref ref-type="bibr" rid="scirp.57497-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.57497-ref22">22</xref>] .</p><p>With respect to the appearance of hypertrophy, no large differences were observed in treated patients, with similar percentages versus the control group. This observation is concurrent with the usual clinical experience, because, so far, no therapy has proven effective in a consistent way for the prevention or treatment of hypertrophic scars or keloids [<xref ref-type="bibr" rid="scirp.57497-ref23">23</xref>] . For now, early identification remains the mainstay for treatment.</p></sec><sec id="s4"><title>4. Conclusions</title><p>As final conclusion, this study presented a group of patients in which the early application of RHO Repavar<sup>&#174;</sup> in</p><fig id="fig5"  position="float"><label><xref ref-type="fig" rid="fig5">Figure 5</xref></label><caption><title> (A) Skin Scar on left side of the face after removal of sutures; (B) Clinical image after 12 weeks of treatment with RHO twice daily</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/13-1050307x9.png"/></fig><fig id="fig6"  position="float"><label><xref ref-type="fig" rid="fig6">Figure 6</xref></label><caption><title> (A) Skin Scar on left side of the face after removal of sutures; (B) Clinical image after 12 weeks of treatment with AHM twice daily</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/13-1050307x10.png"/></fig><p>post-surgical scars generally resulted in a cosmetic improvement thereof. This improvement was observed subjectively, especially at the level of erythema, with significant differences at 6 and 12 weeks, and discoloration and atrophy, with significant differences at 12 weeks.</p><p>This study provides preliminary results that can support the development of other trials providing a larger number of patients and longer follow-up.</p></sec><sec id="s5"><title>Acknowledgements</title><p>This study was sponsored by Ferrer Internacional, SA.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.57497-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Stadelmann, W.K., Digenis, A.G. and Tobin, G.R. (1998) Physiology and Healing Dynamics of Chronic Cutaneous Wounds. American Journal of Surgery, 176, 26-38. http://dx.doi.org/10.1016/S0002-9610(98)00183-4</mixed-citation></ref><ref id="scirp.57497-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Iba, Y., Shibata, A., Kato, M. and Masukawa, T. (2004) Possible Involvement of Mast Cells in Collagen Remodeling in the Late Phase of Cutaneous Wound Healing in Mice. International Immunopharmacology, 4, 1873-1880.http://dx.doi.org/10.1016/j.intimp.2004.08.009</mixed-citation></ref><ref id="scirp.57497-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Arndt, K.A. (2006) Scar Revision. Elsevier, Philadelphia.</mixed-citation></ref><ref id="scirp.57497-ref4"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McGrath</surname><given-names> M.H. </given-names></name>,<etal>et al</etal>. (<year>1990</year>)<article-title>Peptide Growth Factors and Wound Healing</article-title><source> Clinics in Plastic Surgery</source><volume> 17</volume>,<fpage> 421</fpage>-<lpage>432</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.57497-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, I.K., Diegelman, R.F. and Lindblad, W.J. (1992) Wound-Healing: Biochemical and Clinical Aspects. Annals of Surgery, 96, 114. http://dx.doi.org/10.1097/00006534-199211000-00034</mixed-citation></ref><ref id="scirp.57497-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mustoe, T.A., Cooter, R.D., Gold, M.H., Hobbs, F.D., Ramelet, A.A. and Shakespeare, P.G. (2002) International Clinical Recommendations on Scar Management. Plastic and Reconstructive Surgery, 110, 560-571.http://dx.doi.org/10.1097/00006534-200208000-00031</mixed-citation></ref><ref id="scirp.57497-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Dogan, A. and Kazankaya, A. (2006) Properties of Hose Hip Species Grown in Lake Van Basin (Eastern Anatolia Region). Asian Journal of Plant Sciences, 5, 120-122. http://dx.doi.org/10.3923/ajps.2006.120.122</mixed-citation></ref><ref id="scirp.57497-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ozcan, M. (2002) Nutrient Composition of Rose (Rosa canina L.) Seed and Oils. Journal of Medicinal Food, 5, 137-140. http://dx.doi.org/10.1089/10966200260398161</mixed-citation></ref><ref id="scirp.57497-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Valladares, J., Palma, M., Sandoval, C. and Carvajal, F. (1986) Cream Hip Oil (Rosa aff. rubiginosa I.). Part I: Formulation, Preparation and Primary Application in Tissue Regeneration. Annals Real Acad Farm., 52, 597-612.</mixed-citation></ref><ref id="scirp.57497-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Santos, J.S., Vieira, A.B. and Kamada, I. (2009) The Rosehip Not Open Wounds Treatment: A Review. Revista Brasileira de Enfermagem, 62, 457-462. http://dx.doi.org/10.1590/S0034-71672009000300020</mixed-citation></ref><ref id="scirp.57497-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Moreno, J.C., Good, J., Navas, J. and Camacho, F. (1990) Treatment of Cutaneous Ulcers with Musk Rose Oil. Cutan Med Ibero Lat Am., 18, 63-66.</mixed-citation></ref><ref id="scirp.57497-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Camacho, F., Moreno, J.C., Conejo-Mir, J. and Bueno, J. (1994) Treatment of Post-Surgical Scars and Pure Oil Rosehip Seed Defects. Cutan Med Ibero Lat Am., 22, 23-30.</mixed-citation></ref><ref id="scirp.57497-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Marchini, F.B., Martins, D.M., Teves, D.C. and Simoes, M.J. (1988) Rosehip Oil Effect on the Healing of Open Wounds. Revista Paulista de Medicina, 106, 356.</mixed-citation></ref><ref id="scirp.57497-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hakansson, A., Stene, C., Milhaescu, A., Molin, G., Ahrné, S. and Thorlacius, H. (2006) Rose Hip and Lactobacillus plantarum DSM 9843 Reduces Ischemia/Reperfusion Injury in the Mouse Colon. Digestive Diseases and Sciences, 51, 2094-2101. http://dx.doi.org/10.1007/s10620-006-9170-9</mixed-citation></ref><ref id="scirp.57497-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Daels-Rakotoarison, D.A., Gressier, B., Trotin, F., Brunet, C., Luyckx, M. and Dine, T. (2002) Effects of Rosa canina Fruit Extract on Neutrophil Respiratory Burst. Phytotherapy Research, 16, 157-161. http://dx.doi.org/10.1002/ptr.985</mixed-citation></ref><ref id="scirp.57497-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Larsen, E., Kharazmi, A., Christensen, L.P. and Christensen, S.B. (2003) An Antiinflammatory Galactolipid from Rose Hip (Rosa canina) That Inhibits Chemotaxis of Peripheral Blood Neutrophils in Vitro Huma. Journal of Natural Products, 66, 994-995. http://dx.doi.org/10.1021/np0300636</mixed-citation></ref><ref id="scirp.57497-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Robert, P., Carlsson, R.M., Romero, N. and Masson, L. (2003) Stability of Spray-Dried Encapsulated Carotenoid Pigments from Rosehip (Rosa rubiginosa) Oleoresin. Journal of the American Oil Chemists’ Society, 80, 1115-1120.http://dx.doi.org/10.1007/s11746-003-0828-4</mixed-citation></ref><ref id="scirp.57497-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Salminen, J.P., Karonen, M., Lempa, K., Liimatainen, J., Sinkkonen, J. and Lukkarinen, M. (2005) Characterisation of Proanthocyanidin Aglycones and Glycosides from Rose Hips by High-Performance Liquid Chromatography-Mass Spectrometry, and Their Rapid Quantification Together with Vitamin C. Journal of Chromatography A, 1077, 170-180.http://dx.doi.org/10.1016/j.chroma.2005.04.073</mixed-citation></ref><ref id="scirp.57497-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Torok, H.M. and Pillai, R. (2011) Safety and Efficacy of Micronized Tretinoin Gel (0.05%) in Treating Adolescent Acne. Journal of Drugs in Dermatology, 10, 647-652.</mixed-citation></ref><ref id="scirp.57497-ref20"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ting</surname><given-names> W. </given-names></name>,<etal>et al</etal>. (<year>2010</year>)<article-title>Tretinoin for the Treatment of Photodamaged Skin</article-title><source> Cutis</source><volume> 86</volume>,<fpage> 47</fpage>-<lpage>52</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.57497-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Harris, D.W., Buckley, C.C., Ostlere, L.S. and Rustin, M.H. (1991) Topical Retinoic Acid in the Treatment of Acne Scarring Fine. British Journal of Dermatology, 125, 81-82. http://dx.doi.org/10.1111/j.1365-2133.1991.tb06048.x</mixed-citation></ref><ref id="scirp.57497-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">de Limpens A.M., J. (1980) The Local Treatment of Hypertrophic Scars and Keloids with Topical Retinoic Acid. British Journal of Dermatology, 103, 319-323. http://dx.doi.org/10.1111/j.1365-2133.1980.tb07251.x</mixed-citation></ref><ref id="scirp.57497-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Berman, B., Villa, A.M. and Ramirez, C.C. (2004) Novel Opportunities in the Treatment and Prevention of Scarring. Journal of Cutaneous Medicine and Surgery, 8, 32-36. http://dx.doi.org/10.1007/s10227-004-0806-0</mixed-citation></ref></ref-list></back></article>